Dendritic cell therapy of high-grade gliomas
/in Glioblastoma, International Publications, IOZK VeröffentlichungenAn epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
/in Glioblastoma, International PublicationsBrain tumor immunotherapy with type-1 polarizing strategies
/in Glioblastoma, International PublicationsAntigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens
/in Dendritic Cells, Glioblastoma, International PublicationsDCVax-Brain and DC vaccines in the treatment of GBM
/in Dendritic Cells, Glioblastoma, International PublicationsDendritic-cell- and peptide-based vaccination strategies for glioma
/in Glioblastoma, International PublicationsTumour vaccine approaches for CNS malignancies: progress to date
/in Dendritic Cells, Glioblastoma, International PublicationsNewcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma
/in Glioblastoma, International Publications, Newcastle Disease VirusVaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer